ZVRA
$9.23-0.17 (-1.81%)
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
Recent News
GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC
GeneDx Holdings Corp. (NASDAQ:WGS) is one of the most promising stocks under $100 to buy. On March 10, GeneDx and Zevra Therapeutics (NASDAQ:ZVRA) announced a new partnership to launch a sponsored genetic testing program for NPC (Niemann-Pick disease type C). This aims to expand access to GeneDx’s ExomeDx test for patients in the US who […]
Zevra Therapeutics Inc (ZVRA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Driven by ...
Zevra Therapeutics Inc (ZVRA) reports robust financial performance with significant contributions from MIPLYFFA, despite challenges in operating expenses and market variability.
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance
If you are trying to work out whether Zevra Therapeutics is genuinely good value or just a story stock, it helps to start with what the market has been doing with the share price. Zevra Therapeutics shares last closed at US$10.41, with returns of 16.6% over 7 days, 21.5% over 30 days, 24.8% year to date, 31.4% over 1 year and 128.8% over 3 years, while the 5 year return sits at an 8.8% decline. Recent attention on Zevra Therapeutics has focused on its position in the pharmaceuticals and...
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C
GeneDx launches Zevra-backed testing program to expand ExomeDx access for Niemann-Pick Type C, aiming to speed diagnosis and add data to its Infinity dataset.
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge?
In March 2026, GeneDx Holdings Corp. announced a Niemann-Pick disease type C sponsored genetic testing program with Zevra Therapeutics, expanding access to ExomeDx at no cost for eligible U.S. patients and contributing de-identified data to GeneDx Infinity to support faster and more accurate NPC diagnoses. This collaboration strengthens Zevra’s position in rare disease care by directly linking broader genetic testing and earlier NPC identification to potential treatment decisions for its...